April 19, 2023 10:35 AM EDT

In a leaked abstract, J&J's cell therapy appears to have dramatic benefits for multiple myeloma patients

Kyle LaHucik

Senior Reporter

Patients taking Legend Biotech and Johnson & Johnson’s cancer cell therapy Carvykti had a 74% reduction in the risk of multiple myeloma progression or death …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In a leaked abstract, J&J's cell therapy appears to have dramatic benefits for multiple myeloma patients

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026

FDA approves Novavax's Covid vaccine after six-week delay, but for a smaller population

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

In a leaked abstract, J&J's cell therapy appears to have dramatic benefits for multiple myeloma patients